文献速递心力衰竭与心肌病冠心病

VA-ECMO治疗心源性休克中肺淤血的防治

Prevention and treatment of pulmonary congestion in patients undergoing venoarterial extracorporeal membrane oxygenation for cardiogenic shock.
PubMed 文献 · Eur Heart J · 2020-01-01

本文概述了VA-ECMO在心源性休克中的应用原理、重症管理和撤机要点,重点探讨逆行主动脉血流增加左室后负荷导致肺淤血的治疗策略,包括最低流量运行、VA-ECMO联合经皮微轴流泵或VAV-ECMO配置等左室卸载方法,并指出需等待EURO-SHOCK、ANCHOR和ECLS-SHOCK等随机试验评估死亡率影响。

要点

  • VA-ECMO逆行血流增加左室后负荷,可致左室卸载不足和严重肺淤血,限制预后。
  • 左室卸载策略包括最低流量ECMO、联合经皮微轴流泵或VAV-ECMO配置。
  • VA-ECMO能否降低死亡率待EURO-SHOCK、ANCHOR和ECLS-SHOCK等RCT评估。

核心结论

  • VA-ECMO是心源性休克的挽救性干预,但逆行主动脉血流增加左室后负荷可导致肺淤血并限制预后。
  • 左室卸载策略(最低流量、联合微轴流泵或VAV-ECMO)前景可观,但死亡率获益待随机试验验证。

研究设计与样本

  • 重症监护视角的叙述性综述,概述VA-ECMO在心源性休克中的原理、重症管理和撤机。
  • 聚焦逆行血流、左室后负荷增加、左室卸载不足和肺淤血的治疗问题。

主要发现

  • 心源性休克占急性冠脉综合征约10%,当代死亡率高达50%。
  • VA-ECMO逆行主动脉血流增加左室后负荷,导致左室卸载不足和严重肺淤血,限制部分患者预后。
  • 最低流量ECMO、VA-ECMO联合经皮微轴流泵或VAV-ECMO配置是左室卸载和排气策略中最有前景的方法。

临床怎么用

  • VA-ECMO运行时应考虑最低可能流量以减少左室后负荷。
  • 对左室卸载不足和肺淤血患者,可考虑联合经皮微轴流泵或采用VAV-ECMO配置。
  • 心脏团队应关注EURO-SHOCK、ANCHOR和ECLS-SHOCK等随机试验结果以指导VA-ECMO及左室卸载策略。

局限性

  • VA-ECMO能否降低死亡率尚待EURO-SHOCK、ANCHOR和ECLS-SHOCK等前瞻性随机研究评估。
  • 左室卸载的指征、模式和效果需在上述研究的专门亚组分析中探讨。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cardiogenic shock is still a major driver of mortality on intensive care units and complicates ∼10% of acute coronary syndromes with contemporary mortality rates up to 50%. In the meantime, percutaneous circulatory support devices, in particular venoarterial extracorporeal membrane oxygenation (VA-ECMO), have emerged as an established salvage intervention for patients in cardiogenic shock. Venoarterial extracorporeal membrane oxygenation provides temporary circulatory support until other treatments are effective and enables recovery or serves as a bridge to ventricular assist devices, heart transplantation, or decision-making. In this critical care perspective, we provide a concise overview of VA-ECMO utilization in cardiogenic shock, considering rationale, critical care management, as well as weaning aspects. We supplement previous literature by focusing on therapeutic issues related to the vicious circle of retrograde aortic VA-ECMO flow, increased left ventricular (LV) afterload, insufficient LV unloading, and severe pulmonary congestion limiting prognosis in a relevant proportion of patients receiving VA-ECMO treatment. We will outline different modifications in percutaneous mechanical circulatory support to meet this challenge. Besides a strategy of running ECMO at lowest possible flow rates, novel therapeutic options including the combination of VA-ECMO with percutaneous microaxial pumps or implementation of a venoarteriovenous-ECMO configuration based on an additional venous cannula supplying towards pulmonary circulation are most promising among LV unloading and venting strategies. The latter may even combine the advantages of venovenous and venoarterial ECMO therapy, providing potent respiratory and circulatory support at the same time. However, whether VA-ECMO can reduce mortality has to be evaluated in the urgently needed, ongoing prospective randomized studies EURO-SHOCK (NCT03813134), ANCHOR (NCT04184635), and ECLS-SHOCK (NCT03637205). These studies will provide the opportunity to investigate indication, mode, and effect of LV unloading in dedicated sub-analyses. In future, the Heart Teams should aim at conducting a dedicated randomized trial comparing VA-ECMO support with vs. without LV unloading strategies in patients with cardiogenic shock.

来源:Eur Heart J,查看原文。版权归原作者所有。

引用

  1. Lüsebrink E, Orban M, Kupka D, et al. Prevention and treatment of pulmonary congestion in patients undergoing venoarterial extracorporeal membrane oxygenation for cardiogenic shock. Eur Heart J. 2020. PMID: 33099278. doi:10.1093/eurheartj/ehaa547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。